MARKET

PEN

PEN

Penumbra Inc
NYSE
178.43
-11.67
-6.14%
After Hours: 178.43 0 0.00% 16:46 07/26 EDT
OPEN
190.16
PREV CLOSE
190.10
HIGH
191.53
LOW
176.66
VOLUME
552.68K
TURNOVER
0
52 WEEK HIGH
344.04
52 WEEK LOW
170.59
MARKET CAP
6.92B
P/E (TTM)
75.07
1D
5D
1M
3M
1Y
5Y
1D
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
NASDAQ · 1d ago
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
NASDAQ · 4d ago
Weekly Report: what happened at PEN last week (0715-0719)?
Weekly Report · 4d ago
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
NASDAQ · 07/19 12:55
Needham cuts Inari to hold, cites competitive concerns
Needham cuts Inari to hold, cites competitive concerns. The investment bank sees increasing competition in the venous thrombectomy market. Needham says Inari is losing market share to Penumbra. The bank says the shares are now "fairly valued"
Seeking Alpha · 07/18 18:32
Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?
NASDAQ · 07/18 16:54
Med-tech and healthcare stocks with upside during 2Q earnings - Baird
Baird analysts outlined stocks within medical technology where they see an upside during the second quarter’s earnings. Healthcare and med-tech has underperformed the broader market year-to-date. Med-tech was up 3.4% and the U.S. Health care sector was up 8.8%.
Seeking Alpha · 07/18 15:34
AngioDynamics: Lumpy Progress Is Still Progress
AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day. The company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Execution remains the key to the company's success. AngioDynamicics is a name worth considering after years of disappointing results.
Seeking Alpha · 07/17 19:16
More
About PEN
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Webull offers Penumbra Inc stock information, including NYSE: PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.